Testing secondary hypotheses following sequential clinical trials

Biometrics. 2000 Jun;56(2):640-4. doi: 10.1111/j.0006-341x.2000.00640.x.

Abstract

Sequential monitoring in a clinical trial poses difficulty in hypotheses testing on secondary endpoints after the trial is terminated. The conventional likelihood-based testing procedure that ignores the sequential monitoring inflates Type I error and undermines power. In this article, we show that the power of the conventional testing procedure can be substantially improved while the Type I error is controlled. The method is illustrated with a real clinical trial.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Biometry / methods*
  • Child
  • Clinical Trials as Topic / methods*
  • Double-Blind Method
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Likelihood Functions
  • Models, Statistical
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor